🏅 FDA Orphan Designation

Encelto

revakinagene taroretcel-lwey

Manufacturer: Neurotech Pharmaceuticals, Inc.

Indicated for:

NON RARE IN EUROPE: Macular telangiectasia type 2Orphan

FDA-Approved Indications (1)

NON RARE IN EUROPE: Macular telangiectasia type 2Orphan Designation

treatment of adults with idiopathic macular telangiectasia type 2 (MacTel)

Indications & Usage

1 INDICATIONS AND USAGE ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). ENCELTO is an allogeneic encapsulated cell-based gene therapy indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

💙 Support Programs

View all →

Encelto

Neurotech Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.